BioCentury | Jun 23, 2020
Distillery Therapeutics

CDKL5 identified as target in acute kidney injury

DISEASE CATEGORY: Renal INDICATION: Renal damage Inhibiting the kinase CDKL5 could treat acute kidney injury (AKI). In kinome-wide siRNA screens in human and mouse renal tubular epithelial cells, CDKL5 was the gene for which knockdown...
BC Innovations | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
BC Extra | Oct 26, 2018
Politics & Policy

FDA grants first qualification of a clinical safety biomarker

FDA qualified a group of kidney injury biomarkers from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC), marking the first...
BC Innovations | Jul 19, 2018
Translation in Brief

Inflammatory images

A University of Calgary team has implicated the inflammasome in acute kidney injury induced by contrast imaging agents and identified targets that could help prevent it. In patients with diminished renal function, such as those...
BC Innovations | Feb 25, 2016
Translation in Brief

AIMing high

Clearing necrotic debris is a critical step in overcoming acute kidney injury (AKI), but failing to turn off the phagocyte response can lead to renal fibrosis in the long term. A Japanese group has shown...
BC Innovations | Oct 10, 2013
Targets & Mechanisms

KIM-1 driving chronic kidney disease

Kidney injury molecule 1 , a protein that helps overcome acute kidney injury, now has been shown by Harvard Medical School researchers to trigger the onset of chronic kidney disease. 1 Companies modulating the target thus...
BC Innovations | Oct 3, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Mice overexpressing kidney injury molecule 1 (Kim-1) to model chronic kidney disease (CKD) Mice that chronically overexpress Kim-1 in renal epithelial cells could be used...
BC Week In Review | Jul 26, 2010
Company News

Aushon sales and marketing update

Aushon launched its Human Nephrotoxicity Panels worldwide for the quantification of eight biomarkers related to nephrotoxicity in urine samples. The panels include the kidney injury molecule 1 (KIM-1) , clusterin (CLU; APOJ ), tissue inhibitor of...
BC Extra | Jun 24, 2010
Politics & Policy

Japan approves urinary protein biomarkers

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved an application from The Critical Path Institute's Predictive Safety Testing Consortium for qualification of seven urinary biomarkers for preclinical use to detect drug-induced nephrotoxicity. The biomarkers are:...
BC Extra | Jun 13, 2008
Politics & Policy

FDA announces biomarker qualification

FDA said on Thursday that it and EMEA have approved an application from the Predictive Safety Testing Consortium for qualification of seven urinary biomarkers for preclinical use to detect drug-induced nephrotoxicity. The agency's statement is...
Items per page:
1 - 10 of 13